用于203/212Pb治疗对的双功能谷氨酸衍生螯合剂的合成和体内评价。

IF 3.7 Q1 CHEMISTRY, INORGANIC & NUCLEAR
EJNMMI Radiopharmacy and Chemistry Pub Date : 2026-07-04 Epub Date: 2026-09-28 DOI:10.1186/s41181-026-00473-9
Jarred Michael Scaffidi-Muta, Kwong Ching Li, Didier Boucher, Thomas Kryza, William Tieu, Andrew David Abell
{"title":"用于203/212Pb治疗对的双功能谷氨酸衍生螯合剂的合成和体内评价。","authors":"Jarred Michael Scaffidi-Muta,&nbsp;Kwong Ching Li,&nbsp;Didier Boucher,&nbsp;Thomas Kryza,&nbsp;William Tieu,&nbsp;Andrew David Abell","doi":"10.1186/s41181-026-00473-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the <sup>203/212</sup>Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).</p><h3>Results</h3><p>DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with <sup>212</sup>Pb and <sup>203</sup>Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb<sup>2+</sup> complexation than TCMC-MC1RL. Both <sup>212</sup>Pb-labelled compounds remained &gt; 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.</p><h3>Conclusions</h3><p>DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of <sup>203/212</sup>Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616893/pdf/","citationCount":"0","resultStr":"{\"title\":\"Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203/212Pb theranostic pair\",\"authors\":\"Jarred Michael Scaffidi-Muta,&nbsp;Kwong Ching Li,&nbsp;Didier Boucher,&nbsp;Thomas Kryza,&nbsp;William Tieu,&nbsp;Andrew David Abell\",\"doi\":\"10.1186/s41181-026-00473-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the <sup>203/212</sup>Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).</p><h3>Results</h3><p>DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with <sup>212</sup>Pb and <sup>203</sup>Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb<sup>2+</sup> complexation than TCMC-MC1RL. Both <sup>212</sup>Pb-labelled compounds remained &gt; 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.</p><h3>Conclusions</h3><p>DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of <sup>203/212</sup>Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.</p></div>\",\"PeriodicalId\":534,\"journal\":{\"name\":\"EJNMMI Radiopharmacy and Chemistry\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2026-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616893/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Radiopharmacy and Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s41181-026-00473-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/9/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-026-00473-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
引用次数: 0

摘要

背景:放射性金属化肽和小分子的生物分布很大程度上受到金属螯合物所赋予的电荷的影响。因此,仔细微调电荷是优化药代动力学特性的一种有吸引力的方法。为了使这成为一种有效的策略,必须有许多合适的螯合剂可用于给定的放射性金属;每个都有不同的净电荷。本文报道了2-(4,7,10-三(2-氨基-2-氧乙基)-1,4,7,10-四氮杂环十二烷-1-基)戊二酸(DOTAMGA)的合成,这是一种双功能螯合剂,用于203/212Pb治疗对,含有一个负电荷,以前报道的放射性铅螯合剂无法实现。将DOTAMGA掺入到一种靶向黑色素瘤高表达受体黑素皮质素1受体(melanocortin 1 receptor, MC1R)的放射性药物中,并在体内对常用的放射性铅螯合剂1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸酰胺(TCMC)进行了评估。结果:合成了DOTAMGA并将其偶联到MC1R靶向肽MC1RL上,与tcm -MC1RL一起进行后续研究。在一系列与MC1R表达细胞的竞争结合实验中,DOTAMGA-MC1RL和TCMC-MC1RL对MC1R表现出相当的亲和力。在标准放射性标记条件下,DOTAMGA-MC1RL被212Pb和203Pb有效标记,紫外-可见实验表明,Pb2+络合比tcm - mc1rl更快。这两种212pb标记的化合物在人血清中孵育24小时后仍保持bbb90 %的完整性。在携带C57BL/6的B16F0黑色素瘤小鼠中,与tcm - mc1rl相比,DOTAMGA-MC1RL的肝脏摄取减少,尽管也观察到肿瘤摄取减少以及由此导致的肿瘤与器官摄取比。结论:DOTAMGA为优化203/212Pb放射性药物的药代动力学特性提供了一种很有前景的工具,并且由于其独特的电荷特性,是现有放射性铅螯合剂的有益补充。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203/212Pb theranostic pair

Background

The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the 203/212Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).

Results

DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with 212Pb and 203Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb2+ complexation than TCMC-MC1RL. Both 212Pb-labelled compounds remained > 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.

Conclusions

DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of 203/212Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
8.70%
发文量
30
审稿时长
5 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书